Gillian Turner

818 total citations · 1 hit paper
13 papers, 531 citations indexed

About

Gillian Turner is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Gillian Turner has authored 13 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Gillian Turner's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Viral-associated cancers and disorders (3 papers). Gillian Turner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (5 papers) and Viral-associated cancers and disorders (3 papers). Gillian Turner collaborates with scholars based in United Kingdom, Australia and Germany. Gillian Turner's co-authors include David Westerman, Christiane Pott, Andrew W. Roberts, Martin Dreyling, Kate Burbury, Mark A. Dawson, Rodney J. Hicks, John F. Seymour, Sarah‐Jane Dawson and Juliana Di Iulio and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Gillian Turner

12 papers receiving 521 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

2018 274 citations Constantine S. Tam, Mary Ann Anderson et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gillian Turner

Since Specialization

Citations

This map shows the geographic impact of Gillian Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gillian Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gillian Turner more than expected).

Fields of papers citing papers by Gillian Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gillian Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gillian Turner. The network helps show where Gillian Turner may publish in the future.

Co-authorship network of co-authors of Gillian Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Gillian Turner. A scholar is included among the top collaborators of Gillian Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gillian Turner. Gillian Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Long Term Responses to Venetoclax and Ibrutinib in Mantle Cell Lymphoma Are Associated with Immunological Recovery and Prognostic Changes in Inflammatory Biomarkers 2019 ·Blood ·Joanne E. Davis, Sasanka M. Handunnetti, (unknown), Gillian Turner, Mary Ann Anderson, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, David Ritchie, Rachel Koldej	0
2	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma breakdown → 2018 ·New England Journal of Medicine ·Constantine S. Tam, Mary Ann Anderson, Christiane Pott, Rishu Agarwal, Sasanka M. Handunnetti, Rodney J. Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David Westerman, Stephen Lade, Martin Dreyling, Sarah‐Jane Dawson, Mark A. Dawson, John F. Seymour, Andrew W. Roberts	274
3	Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study. 2017 ·Journal of Clinical Oncology ·Constantine S. Tam, Andrew W. Roberts, Mary Ann Anderson, Sarah‐Jane Dawson, Rodney J. Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David Westerman, Rishu Agarwal, Christiane Pott, Martin Dreyling, Mark A. Dawson, John F. Seymour	6
4	Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib 2015 ·British Journal of Haematology ·(unknown), (unknown), Gillian Turner, Kristian M. Bowles	1
5	Resolution of chronic severe refractory thrombocytopenia after treatment of hypothyroidism 2004 ·Journal of Clinical Pathology ·Kristian M. Bowles, Gillian Turner, J. Z. Wimperis	14
6	Molecular Analysis of Chromosome Aberrations in Hematological Malignancies: Southern Hybridization 2003 ·Humana Press eBooks ·David L. Saltman, Stephen P. Hunger, Gillian Turner	1
7	A multicentre, open, non‐comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony‐stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation 2001 ·British Journal of Haematology ·Graham Jackson, P R Taylor, Graeme Smith, R. E. Marcus, Alastair G. Smith, Patrick Chu, Timothy J. Littlewood, Andrew Duncombe, Michael Hutchinson, Atul Mehta, S.A. Johnson, Peter Carey, M.J. Mackie, Peter Ganly, Gillian Turner, Miriam Deane, Steve Schey, Jonathan Brookes, Susan M. Tollerfield, Marcia Wilson	99
8	A case of mature B‐cell ALL with coexistence of t(1;19) and t(14;18) and expression of the E2A/PBX1 fusion gene 1996 ·British Journal of Haematology ·David W. Rowe, (unknown), Julie Irving, Linda Hogarth, Andrew G. Hall, Gillian Turner	9
9	Detection of t(14;18) in British follicular lymphoma using cytogenetics, Southern blotting and the polymerase chain reaction 1995 ·British Journal of Haematology ·Gillian Turner, Fiona M. Ross, A S Krajewski	25
10	Transfusion‐associated graft‐versus‐host disease in fludarabine‐treated B‐chronic lymphocytic leukaemia 1994 ·British Journal of Haematology ·Z. T. Maung, (unknown), Graham Jackson, Gillian Turner, (unknown), P. J. Hamilton	40
11	What is marrow fibrosis after treatment of neuroblastoma? 1993 ·Journal of Clinical Pathology ·Gillian Turner, M M Reid	4
12	Establishment of a karyotypically normal B-chronic lymphocytic leukemia cell line; Evidence of leukemic origin by immunoglobulin gene rearrangement 1990 ·Leukemia Research ·David L. Saltman, (unknown), Fiona M. Ross, James A. Ross, Gillian Turner, Keith Guy	41
13	Telomeric associations in a lymphoblastoid cell line from a patient with B-cell follicular lymphoma 1989 ·Cytogenetic and Genome Research ·David L. Saltman, F. M. Ross, Judy Fantes, Robin C. Allshire, Gillian Turner, (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact